Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2012-05-21 | Mr. Enright is a venture capitalist with extensive finance and biotechnology industry experience; no software or programming skills indicated. |
| 2013-04-17 | Mr. Enright received a B.S. from Stanford University and an M.B.A. from the Wharton School at the University of Pennsylvania. He is a venture capital investor focused on life science companies. |
| 2014-04-07 | Mr. Enright has a B.S. from Stanford University and an M.B.A. from Wharton, with experience in pharmaceutical investments. |
| 2015-04-20 | Mr. Enright received a B.S. from Stanford University and an M.B.A. from the Wharton School at the University of Pennsylvania. As a venture capital investor focused on life science companies and someone who has worked in the pharmaceutical industry, Mr. Enright brings to our Board both operating experience and financial expertise in the life sciences industry. |
| 2016-04-22 | Mr. Enright is founder of Longitude Capital, a venture capital firm focused on pharmaceutical and medical technology companies, and holds a B.S. from Stanford University and an M.B.A. from Wharton. |
| Filing Date | Source Excerpt |
|---|---|
| 2015-06-10 | Mr. Enright received a B.S. from Stanford University and a M.B.A. from the Wharton School at the University of Pennsylvania. Based on his experience as a venture capital investor focused on life sciences companies and past work in the pharmaceutical industry, Mr. Enright brings to our board of directors over 25 years of operating experience and financial expertise in the life sciences industry. |
| 2016-06-20 | Mr. Enright has served as a member of our board of directors since the closing of the Azur Merger in January 2012 and was a director of Jazz Pharmaceuticals, Inc. from 2009 until the closing of the Azur Merger. Since 2006, Mr. Enright has served as a Managing Director of Longitude Capital, a venture capital firm, of which he is a founder. From 2002 through 2006, Mr. Enright was a Managing Director of Pequot Ventures, a venture capital investment firm, where he co-led the life sciences investment practice. He currently serves on the boards of directors of Aimmune Therapeutics, Inc., a biopharmaceutical company, Corcept Therapeutics Incorporated, a pharmaceutical company, Esperion Therapeutics, Inc., a pharmaceutical company, and several privately held companies. Mr. Enright received a B.S. from Stanford University and an M.B.A. from the Wharton School at the University of Pennsylvania. |
| 2017-06-20 | Mr. Enright has served as a member of our board of directors since the closing of the Azur Merger in January 2012 and was a director of Jazz Pharmaceuticals, Inc. from 2009 until the closing of the Azur Merger. Since 2006, Mr. Enright has served as a Managing Director of Longitude Capital, a venture capital firm, of which he is a founder. From 2002 through 2006, Mr. Enright was a Managing Director of Pequot Ventures, a venture capital investment firm, where he co-led the life sciences investment practice. He currently serves on the boards of directors of Aimmune Therapeutics, Inc., a biopharmaceutical company, and several privately-held companies. Previously, Mr. Enright served on the boards of directors of Esperion Therapeutics, Inc., a pharmaceutical company, from April 2013 to June 2016, and Corcept Therapeutics Incorporated, a pharmaceutical company, from April 2008 to May 2017. Mr. Enright received a B.S. from Stanford University and an M.B.A. from the Wharton School at the University of Pennsylvania. |
| 2018-06-15 | Mr. Enright brings to our board of directors over 25 years of operating experience and financial expertise in the life sciences industry. |
| 2019-06-14 | Mr. Enright has served as a member of our board of directors since the closing of the Azur Merger in January 2012 and was a director of Jazz Pharmaceuticals, Inc. from 2009 until the closing of the Azur Merger. Since 2006, Mr. Enright has served as Managing Director of Longitude Capital, a venture capital firm, of which he is a founder. |
| 2020-06-12 | Based on his experience as a venture capital investor focused on life sciences companies and his past work in the pharmaceutical industry, Mr. Enright brings to our board of directors over 30 years of operating experience and financial expertise in the life sciences industry. |
| 2021-06-11 | Mr. Enright received a B.S. in Biological Sciences from Stanford University and an M.B.A. from the Wharton School of the University of Pennsylvania. |
| 2021-08-30 | Patrick G. Enright included in the list of directors with no indication of software or technical background. |
| 2022-06-13 | Based on his experience as a venture capital investor focused on life sciences companies and his past work in the pharmaceutical industry, Mr. Enright brings to our board of directors over 30 years of operating experience and financial expertise in the life sciences industry. |
| 2023-06-16 | Mr. Enright co-founded Longitude Capital, a healthcare venture capital firm, and has a B.S. in Biological Sciences and an M.B.A. |
| 2024-06-14 | Mr. Enright brings to our board operating experience and financial expertise in the life sciences industry. |
Data sourced from SEC filings. Last updated: 2026-02-03